Holen Sie sich die Stockscreener-App
49.25
0.28%
-0.14
Vorhandelsmarkt:
49.00
-0.25
-0.51%
Schlusskurs vom Vortag:
$49.39
Offen:
$49.43
24-Stunden-Volumen:
364.96K
Relative Volume:
0.62
Marktkapitalisierung:
$2.03B
Einnahmen:
$17.39M
Nettoeinkommen (Verlust:
$-135.89M
KGV:
-10.61
EPS:
-4.64
Netto-Cashflow:
$-123.00M
1W Leistung:
+11.63%
1M Leistung:
+3.71%
6M Leistung:
+32.86%
1J Leistung:
+43.09%
1-Tages-Spanne:
$48.69
$50.30
1-Wochen-Bereich:
$42.90
$50.30
52-Wochen-Spanne:
$20.08
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Firmenname
Tarsus Pharmaceuticals Inc
Sektor
Branche
Telefon
(949) 409-9820
Adresse
15440 LAGUNA CANYON ROAD, IRVINE
Vergleichen Sie TARS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
49.25 | 2.03B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-20 | Eingeleitet | Goldman | Neutral |
| 2023-07-18 | Eingeleitet | William Blair | Outperform |
| 2023-05-18 | Eingeleitet | Guggenheim | Buy |
| 2022-08-01 | Eingeleitet | Barclays | Overweight |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-23 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-10 | Eingeleitet | BofA Securities | Buy |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-11-10 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Tarsus Pharmaceuticals Inc Aktie (TARS) Neueste Nachrichten
Learn to Evaluate (TARS) using the Charts - news.stocktradersdaily.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by JPMorgan Chase & Co. - Defense World
Midday Stock Roundup: Healthcare, medtech stocks tumble - Orange County Business Journal
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Vanguard Group Inc. - Defense World
Papulopustular Rosacea Market Expected to Experience Major Growth by 2034, According to DelveInsight | Sol-Gel Technologies, Galderma, CollaGenex Pharma, Tarsus Pharma, Pfizer - Barchart.com
KLP Kapitalforvaltning AS Invests $299,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Sei Investments Co. Purchases 12,689 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
HighTower Advisors LLC Invests $207,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Raymond James Financial Inc. Makes New $1.11 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(TARS) Trading Report - news.stocktradersdaily.com
With Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) It Looks Like You'll Get What You Pay For - simplywall.st
Teacher Retirement System of Texas Has $438,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Fastest-Growing Public Cos. Ride Healthcare Boom - Orange County Business Journal
Tarsus Pharmaceuticals CEO sells $300,000 in stock By Investing.com - Investing.com Canada
Swiss National Bank Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals CEO sells $300,000 in stock - Investing.com India
4,031 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Victory Capital Management Inc. - Defense World
Where are the Opportunities in (TARS) - news.stocktradersdaily.com
Tarsus Pharmaceuticals CFO Jeffrey Farrow sells $178,306 in stock By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals CEO Bobak Azamian sells $1.16 million in stock By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals chief commercial officer sells $505,856 in stock By Investing.com - Investing.com India
Tarsus Pharmaceuticals COO Neervannan Seshadri sells $363,141 in stock By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals’ general counsel sells shares worth $463,765 By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals CFO Jeffrey Farrow sells $178,306 in stock - Investing.com
Tarsus Pharmaceuticals’ general counsel sells $463,765 in stock - Investing.com India
Tarsus Pharmaceuticals CEO Bobak Azamian sells $1.16 million in stock - Investing.com
Tarsus Pharmaceuticals’ general counsel sells shares worth $463,765 - Investing.com
Tarsus Pharmaceuticals chief commercial officer sells $505,856 in stock - Investing.com
Tarsus Pharmaceuticals’ HR chief sells shares worth $321,323 - Investing.com
Tarsus Pharmaceuticals COO Neervannan Seshadri sells $363,141 in stock - Investing.com
Tarsus Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Tarsus Pharmaceuticals completes $134.8M stock offering By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals completes $134.8M stock offering - Investing.com India
Tarsus prices $125M stock offering - MSN
Tarsus Pharma dips after upsized $125 mln stock offering - TradingView
Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering -March 13, 2025 at 03:44 am EDT - Marketscreener.com
Tarsus Pharmaceuticals launches $100 million stock offering - Investing.com Australia
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewswire
Tarsus Secures Massive $125M Capital Raise as Investors Rush Into Upsized Offering - StockTitan
Tarsus Announces Pricing Of Upsized $125 Million Public Offering -March 12, 2025 at 09:50 pm EDT - Marketscreener.com
Tarsus Pharmaceuticals dips on planned $100 million equity raise - TradingView
Tarsus Pharmaceuticals launches $100 million stock offering By Investing.com - Investing.com Canada
Tarsus Announces Proposed $100.0 Million Public Offering - The Manila Times
Finanzdaten der Tarsus Pharmaceuticals Inc-Aktie (TARS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):